Stay updated on SHR6390 & Pyrotinib in HER2+ Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the SHR6390 & Pyrotinib in HER2+ Breast Cancer Clinical Trial page.

Latest updates to the SHR6390 & Pyrotinib in HER2+ Breast Cancer Clinical Trial page
- Check2 days agoChange DetectedThe page’s displayed software/version label changes from Revision v3.5.2 to v3.5.3, reflecting a site update rather than any modification to the clinical trial’s study information.SummaryDifference0.1%

- Check9 days agoChange DetectedNew revision entry v3.5.2 added to the history, replacing the previous v3.5.0 entry.SummaryDifference0.1%

- Check16 days agoNo Change Detected
- Check38 days agoChange DetectedA new revision entry v3.5.0 was added to the record history. The previous revision v3.4.3 was removed.SummaryDifference0.1%

- Check45 days agoChange DetectedRevision: v3.4.3 was added to the history. Revision: v3.4.2 was removed from the history.SummaryDifference0.1%

- Check73 days agoChange DetectedAdded a new revision label (v3.4.2) to the record history and removed older notices (v3.4.1 and the funding-status notice). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.9%

- Check80 days agoChange DetectedA government funding lapse notice was added and the record history shows a new Revision: v3.4.1 (replacing v3.4.0); these are administrative updates and do not affect core study data. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.9%

Stay in the know with updates to SHR6390 & Pyrotinib in HER2+ Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SHR6390 & Pyrotinib in HER2+ Breast Cancer Clinical Trial page.